Evaluasi risiko polifarmasi dan interaksi obat pada pasien chronic kidney disease di rumah sakit x provinsi Banten

Santosa, Lie, Christian (2023) Evaluasi risiko polifarmasi dan interaksi obat pada pasien chronic kidney disease di rumah sakit x provinsi Banten. Bachelor thesis, Universitas Pelita Harapan.

Preview	Text (Title) Title.pdf.pdf Available under License Creative Commons Attribution Non-commercial Share Alike. Download (31kB) | Preview
Preview	Text (Abstract) Abstract.pdf.pdf Available under License Creative Commons Attribution Non-commercial Share Alike. Download (55kB) | Preview
Preview	Text (ToC) ToC.pdf.pdf Available under License Creative Commons Attribution Non-commercial Share Alike. Download (197kB) | Preview
	Text (Chapter1) Chapter1.pdf.pdf Restricted to Registered users only Available under License Creative Commons Attribution Non-commercial Share Alike. Download (56kB)
	Text (Chapter2) Chapter2.pdf.pdf Restricted to Registered users only Available under License Creative Commons Attribution Non-commercial Share Alike. Download (631kB)
	Text (Chapter3) Chapter3.pdf.pdf Restricted to Registered users only Available under License Creative Commons Attribution Non-commercial Share Alike. Download (232kB)
	Text (Chapter4) Chapter4.pdf.pdf Restricted to Registered users only Available under License Creative Commons Attribution Non-commercial Share Alike. Download (324kB)
	Text (Chapter5) Chapter5.pdf.pdf Restricted to Registered users only Available under License Creative Commons Attribution Non-commercial Share Alike. Download (51kB)
Preview	Text (Bibliography) Bibliography.pdf Available under License Creative Commons Attribution Non-commercial Share Alike. Download (185kB) | Preview
	Text (Appendices) Appendices.pdf Restricted to Repository staff only Available under License Creative Commons Attribution Non-commercial Share Alike. Download (1MB)

Abstract

Pasien yang terdiagnosa CKD di Indonesia mengalami peningkatan dari tahun 2013 yaitu 2% menjadi 3,8% pada tahun 2018. Polifarmasi banyak ditemukan pada pasien CKD terutama pada pasien CKD dengan penyakit penyerta. CKD disertai dengan penyakit penyerta akan membuat pengobatannya menjadi lebih kompleks dan mahal. Penelitian ini dilakukan untuk menilai hubungan antara polifarmasi dengan interaksi obat pada pasien CKD. Analisis data akan dilakukan secara deskriptif pada pasien CKD di rumah sakit x pada periode 1 Oktober hingga 31 Desember 2022 dan data ditampilkan dalam bentuk tabel dan grafik. Data pasien dikumpulkan berdasarkan rekam medis, resep dianalisa dan interaksi obat diidentifikasi menggunakan interaction checker melalui www.drugs.com dan medscape. Dari 84 pasien terdapat 626 potensi interaksi obat mencangkup 152 (24,28%) interaksi obat dengan tingkat keparahan minor, 434 (69,33%) interaksi obat dengan tingkat keparahan moderate, dan 40 (6,39%) interaksi obat dengan tingkat keparahan major. Pasien CKD yang memiliki satu atau lebih penyakit penyerta akan meningkatkan risiko terjadinya polifarmasi dan terjadi peningkatan risiko terjadinya interaksi obat./Patients diagnosed with CKD in Indonesia increased from 2013 from 2% to 3.8% in 2018. Polypharmacy is widely found in CKD patients, especially in CKD patients with comorbidities. CKD accompanied by comorbidities will make treatment more complex and expensive. This study was conducted to assess the relationship between polypharmacy and drug interactions in CKD patients. Data analysis will be carried out descriptively on CKD patients in hospital x in the period October 1 to December 31, 2022 and the data is displayed in the form of tables and graphs. Patient data was collected based on medical records, prescriptions were analyzed and drug interactions were identified using interaction checkers through www.drugs.com and medscape. Of the 84 patients, there were 626 potential drug interactions including 152 (24.28%) drug interactions with minor severity, 434 (69.33%) drug interactions with moderate severity, and 40 (6.39%) drug interactions with major severity. CKD patients who have one or more comorbidities will increase the risk of polypharmacy and an increased risk of drug interactions.

Actions (login required)

View Item